Explore daily insights on
Veru Stock Surges 167% on Novo Nordisk Obesity Trial Supply Agreement
- Veru secured a clinical supply agreement with Novo Nordisk to provide Wegovy for its Phase 2b PLATEAU obesity trial.
- Shares of Veru surged 167% intraday to a daily high of $7.33 on June 4, closing at $4.23 on a massive volume of 88.97 million shares.
- The deal validates Veru's combination therapy approach and provides a massive liquidity boost to the micro-cap biotech firm.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 2 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
Veru's agreement was signed on June 2, 2026 and reported on June 4, 2026. Daily price records show VERU closed at $4.23 on June 4 with 88,970,324 shares traded (compared to a 5-day average of ~64,000 shares), reaching an intraday high of $7.33 and closing at $3.40 on June 5 on 10,733,700 shares.